Wells Fargo & Company Inhibikase Therapeutics, Inc. Transaction History

Wells Fargo & Company

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.54 - $0.91 $549 - $925	1,017 Added 747.79%	1,153 $0
Q4 2022 Feb 13, 2023	BUY	$0.45 - $0.78 $1 - $3	4 Added 3.03%	136 $0
Q3 2022 Nov 14, 2022	SELL	$0.76 - $1.11 $0 - $1	-1 Reduced 0.75%	132 $0
Q2 2022 Aug 12, 2022	BUY	$0.63 - $1.44 $6 - $15	11 Added 9.02%	133 $0
Q3 2021 Nov 15, 2021	BUY	$1.79 - $2.81 $196 - $309	110 Added 916.67%	122 $0

Q1 2021 May 13, 2021	BUY	$5.2 - $7.95 $62 - $95	12 New	12 $0

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $33.8M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.